Brokerages Set Prestige Consumer Healthcare Inc. (NYSE:PBH) PT at $85.25

Prestige Consumer Healthcare Inc. (NYSE:PBH) has been given an average rating of “Moderate Buy” by the four analysts that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $85.25.

Several equities analysts have commented on PBH shares. StockNews.com downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a report on Tuesday. Jefferies Financial Group reiterated a “hold” rating and issued a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price target on the stock. in a report on Monday. Finally, DA Davidson restated a “buy” rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a report on Monday, November 11th.

Prestige Consumer Healthcare Stock Down 0.8 %

Shares of PBH stock opened at $83.55 on Monday. Prestige Consumer Healthcare has a 52-week low of $57.95 and a 52-week high of $86.36. The stock has a market cap of $4.13 billion, a price-to-earnings ratio of 20.33, a PEG ratio of 2.37 and a beta of 0.49. The firm’s 50-day moving average is $77.55 and its 200-day moving average is $72.27. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.09. The company had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The business’s revenue was down .9% on a year-over-year basis. During the same period last year, the firm posted $1.07 earnings per share. Sell-side analysts predict that Prestige Consumer Healthcare will post 4.44 EPS for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, CEO Ronald M. Lombardi sold 10,875 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the transaction, the chief executive officer now directly owns 320,952 shares in the company, valued at approximately $26,510,635.20. The trade was a 3.28 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Adel Mekhail sold 9,063 shares of the stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the sale, the executive vice president now owns 18,365 shares in the company, valued at $1,505,930. This represents a 33.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,810 shares of company stock valued at $3,187,300 in the last quarter. Company insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of PBH. Quest Partners LLC grew its holdings in shares of Prestige Consumer Healthcare by 2,826.7% during the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after purchasing an additional 424 shares during the last quarter. Gladius Capital Management LP bought a new stake in shares of Prestige Consumer Healthcare during the second quarter worth $35,000. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Prestige Consumer Healthcare by 562.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after buying an additional 433 shares in the last quarter. ORG Partners LLC bought a new position in shares of Prestige Consumer Healthcare in the 2nd quarter valued at $39,000. Finally, nVerses Capital LLC boosted its holdings in shares of Prestige Consumer Healthcare by 200.0% during the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company’s stock valued at $43,000 after acquiring an additional 400 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.